Increased plasma levels of soluble CD40, together with the decrease of TGF beta 1, as possible differential markers...

Area of Science:

• Neuroscience
• Immunology
• Biochemistry

Background:

• Alzheimer's disease (AD) is a leading cause of dementia, characterized by neuroinflammation.
• Activated microglia and inflammatory proteins are key features in AD pathogenesis.
• Soluble CD40 (sCD40) and transforming growth factor-beta 1 (TGF-beta1) are implicated in AD.

Purpose of the Study:

• To investigate circulating levels of sCD40 and TGF-beta1 as potential Alzheimer's disease biomarkers.
• To explore the role of these inflammatory mediators in AD pathogenesis.
• To assess if these markers can differentiate AD from other neurological conditions.

Main Methods:

• Blood samples collected from 33 possible late-onset AD patients, 40 age-matched healthy controls, and 11 young healthy controls.
• Quantification of plasma sCD40 and TGF-beta1 levels.
• ApoE epsilon 4 allele genotyping performed for correlation analysis.

Main Results:

• Significantly elevated plasma sCD40 levels in AD patients compared to healthy controls.
• Concomitant significant decrease in plasma TGF-beta1 concentration in AD patients.
• No correlation observed between these marker variations and ApoE epsilon 4 allele status.
• No similar changes detected in Parkinson's disease or non-AD dementia patients.

Conclusions:

• Plasma sCD40 and TGF-beta1 levels may serve as differential biomarkers for Alzheimer's disease.
• These markers could potentially support pre-mortem clinical diagnosis of late-onset AD.
• Findings suggest a specific inflammatory profile associated with AD.